Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease

NEUROBIOLOGY OF AGING

卷:34

Article

Soldan, Anja¹  Pettigrew, Corinne¹  Li, Shanshan²  Wang, Mei-Cheng²  Moghekar, Abhay¹  Selnes, Ola A.¹  Albert, Marilyn¹  O'Brien, Richard¹ 

[1] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA

关键词: Cognitive reserve;    Preclinical Alzheimer's disease;    Mild cognitive impairment;    Cerebrospinal fluid;    Tau;    Amyloid;    Cohort studies;    Biomarkers;   

DOI  :  10.1016/j.neurobiolaging.2013.06.017

来源: Elsevier

【 摘 要 】

The levels of beta-amyloid (A beta) and phosphorylated tau (p-tau), as measured in cerebrospinal fluid, have been associated with the risk of progressing from normal cognition to onset of clinical symptoms during preclinical Alzheimer's disease. We examined whether cognitive reserve (CR) modifies this association. Cerebrospinal fluid was obtained at baseline from 239 participants (mean age, 57.2 years) who had been followed for up to 17 years with clinical and cognitive assessments (mean follow-up, 8 years). A composite score based on the National Adult Reading Test, vocabulary, and years of education at baseline was used as an index of CR. Cox regression models showed that the increased risk of progressing from normal cognition to symptom onset was associated with lower CR, lower baseline A beta, and higher baseline p-tau. There was no interaction between CR and A beta, suggesting that the protective effects of higher CR are equivalent across the observed range of amyloid levels. In contrast, both tau and p-tau interacted with CR, indicating that CR was more protective at lower levels of tau and p-tau. (C) 2013 Elsevier Inc. All rights reserved.

【 授权许可】

Free